Please login to the form below

Not currently logged in
Email:
Password:

ViiV

This page shows the latest ViiV news and features for those working in and with pharma, biotech and healthcare.

Dovato approval key for Glaxo in HIV treatment

Dovato approval key for Glaxo in HIV treatment

those who would otherwise be precluded from receiving [ViiV's] Triumeq (abacavir/dolutegravir/lamivudine) due to abacavir hypersensitivity.”. ... This combines ViiV’s integrase inhibitor cabotegravir and Johnson &Johnson’s non-nucleoside reverse

Latest news

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    drugs, the injectable treatment was preferred by “nearly all” the subjects in the trials, according to ViiV’s chief scientific and medical officer John Pottage (below). ... Having an injectable alternative could help ViiV’s ambition of becoming

  • Havas Lynx Group scoops nine Golds at PM Society Awards Havas Lynx Group scoops nine Golds at PM Society Awards

    Other Gold winners included Aspen, Boeringher Ingelheim, Galderma, Johnson &Johnson, Mundipharma, Napp, Novartis, PTC Therapeutics, Shire, Teva, Tillotts Pharma and ViiV. ... Craft Award for Film &Animation (HCPs): Havas Lynx for AstraZeneca. Craft Award

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    Gilead is still a dominant player in HIV – although its jostling for market share with ViiV.

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    GSK’s ViiV subsidiary and Gilead that offer multiple drugs in a single tablet, simplifying treatment.  Sales came in at $860m in the first nine months of this year, a fall ... Gilead and ViiV that aim to increase efficacy and/or reduce exposure to

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    dominant player, but has been losing market share to ViiV over the last few years. ... Going down the injectable route provides another option to patients, although ViiV and Janssen still have to navigate a phase 3 trials programme.

More from news
Approximately 33 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share.

  • Stronger together Stronger together

    The top-down approach has certainly been in evidence at ViiV, the joint venture between GlaxoSmithKline, Pfizer and Shionogi, as its CEO Dominique Limet told the eyeforpharma audience. ... This year's survey of European patient groups marked the second

  • Deal Watch December 2015 Deal Watch December 2015

    2, 075. BMS (HIV business). GSK (ViiV). Acquisition - asset. Acquisition of HIV product pipeline from BMS incl.

  • Understanding the patient ecosystem Understanding the patient ecosystem

    The continued success of the ViiV pharma group, which has three times now been deemed the most reputable and engaged pharma firm in the eyes of patient charities, also highlights how

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    With the recent launch of Triumeq from ViiV – whose owner, GSK, brought the first HIV treatment to market in the late 1980s – this looks set to change. ... Viiv's Triumeq is now following a similar pattern. Although it gained EU approval in September

More from intelligence
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics